Metropolitan Life Insurance CO Point Biopharma Global Inc. Transaction History

Metropolitan Life Insurance CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.67 - $9.71 $6,103 - $8,884	915 Added 18.28%	5,920 $39,000
Q2 2023 Aug 10, 2023	BUY	$6.86 - $10.86 $2,908 - $4,604	424 Added 9.26%	5,005 $45,000
Q1 2023 May 15, 2023	SELL	$6.78 - $8.1 $6,034 - $7,209	-890 Reduced 16.27%	4,581 $33,000
Q4 2022 Jun 14, 2023	BUY	$5.72 - $9.78 $5,090 - $8,704	890 Added 19.43%	5,471 $39.9 Million
Q4 2022 Mar 30, 2023	BUY	$5.72 - $9.78 $4,118 - $7,041	720 Added 15.15%	5,471 $39,000
Q4 2022 Feb 15, 2023	BUY	$5.72 - $9.78 $4,118 - $7,041	720 Added 15.15%	5,471 $39,000
Q3 2022 Jun 14, 2023	BUY	$7.24 - $10.31 $1,230 - $1,752	170 Added 3.71%	4,751 $36.7 Million
Q2 2022 Jun 20, 2023	BUY	$5.6 - $9.5 $951 - $1,615	170 Added 3.71%	4,751 $32,000
Q2 2022 Mar 30, 2023	SELL	$5.6 - $9.5 $4,031 - $6,840	-720 Reduced 13.16%	4,751 $32,000
Q2 2022 Aug 11, 2022	BUY	$5.6 - $9.5 $26,605 - $45,134	4,751 New	4,751 $32,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.